Sutro Biopharma Announces Participation at the 16th World ADC London Summit

Core Insights - Sutro Biopharma, Inc. is participating in the 16th World ADC London Summit from February 23-26, 2026, showcasing its advancements in antibody drug conjugates (ADCs) [1] Company Overview - Sutro Biopharma is a clinical-stage oncology company focused on developing next-generation ADCs that aim to improve drug exposure, reduce side effects, and expand treatable tumor types [4] - The company utilizes a cell-free platform to produce single- and dual-payload ADCs, targeting large oncology markets with limited treatment options [4] Event Participation - Sutro's participation includes several panel discussions featuring Hans-Peter Gerber, Ph.D., covering topics such as ADC licensing, innovation in ADC differentiation, and the efficacy and safety profiles of dual payload ADCs [6]